|Grant, 10/12 |
National Cancer Institute
RXi Pharmaceuticals Corporation is a discovery-stage biopharmaceutical company pursuing therapeutics based on ribonucleic acid (RNA) interference (RNAi). RNAi therapeutic platform includes two components: Novel RNAi Compounds and Advanced Delivery Technologies. The Company has developed a number of forms of rxRNA compounds. These RNAi compounds include rxRNAori, rxRNAsolo and sd-rxRNA, or self delivering RNA. The suite of delivery technologies is comprised of delivery vehicles, which could be combined with various rxRNA compounds, as well as sd-rxRNA compounds, which are chemically modified and have the property of entering cells and tissues to effect silencing without the need for any additional delivery vehicle.